---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-356915"
form_type: "8-K"
ticker: "JAGX"
cik: "0001585608"
company_name: "Jaguar Health, Inc."
filed_at: "2026-08-19T20:15:13+00:00"
generated_at: "2026-08-19T20:16:09.120397+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Jaguar Health Q2 2026 revenue down 59% YoY; net loss widens to $12.7M

## Summary
- Total net revenue $1.225M vs $2.979M in Q2 2025 (-59%); product revenue down 60% to $1.18M.
- Net loss attributable to common stockholders $12.69M vs $10.41M; EPS -$15.68 vs -$358.94.
- Sales/marketing expense fell $2.5M after Future Pak licensing Jan 12, 2026; cost of product revenue rose to ~$1.0M.
- MVID NDA package expected ready end-2026; submission planned Q2 2027; crofelemer MVID data showed parenteral support reduction up to 48%.
- Non-GAAP recurring EBITDA loss widened to $8.4M; loss on debt extinguishment $3.5M.

## SEC filing metadata
- accession: 0001193125-26-356915
- form_type: 8-K
- ticker: JAGX
- cik: 0001585608
- company_name: Jaguar Health, Inc.
- filed_at: 2026-08-19T20:15:13+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1585608/000119312526356915/0001193125-26-356915-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1585608/000119312526356915/d380271d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-356915
- JSON: https://secwatch.observer/filing/0001193125-26-356915.json
- Plain text: https://secwatch.observer/filing/0001193125-26-356915.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.